Sally Lawlor joined Quoin Pharmaceuticals in August 2025 as Chief Financial Officer. She brings 20 years of finance experience across Big Four accounting and senior roles in public and private companies. Most recently, she held senior finance positions at Sebela Pharmaceuticals, overseeing audited financials under U.S. GAAP and IFRS, FP&A, budgeting, cash management, and global tax compliance. Previously, she served at Aptiv Plc as EMA Tax Lead and Director of Global Tax Planning. Earlier, Lawlor spent over a decade with KPMG advising multinational clients in the pharmaceutical and technology sectors. She is a Fellow of Chartered Accountants Ireland, a member of the Irish Taxation Institute, and holds a bachelor’s degree in Law and German from University College Cork.
Rare diseases are only rare if you don’t live with one.®
Subscribe to Email Alerts
Sign up for alerts to stay up to date on Quoin Pharmaceuticals.
Latest News:
Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome
Confirmation Received from MHLW That QRX003 Qualifies for Both Orphan Drug Designation and Fast Track Regulatory Review Status Quoin Initiating the Establishment of a Japanese Subsidiary to Facilitate Self-Commercialization of QRX003 in Japan, if Approved Orphan Drug...
Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome
If granted, QRX003 could be approved for sale and reimbursement in Saudi Arabia as a treatment for Netherton Syndrome in 2H 2026 QRX003 could become the first ever approved treatment for Netherton Syndrome ASHBURN, Va., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Quoin...